表紙
市場調查報告書
商品編碼
980006

Transthyretin型心類澱粉蛋白沉積症治療市場 - 類型、藥物類型、流通管道、各地區:市場規模、佔有率、展望、機會、分析 (2020-2027年)

Transthyretin Amyloid Cardiomyopathy Treatment Market, by Type, by Drug Type, by Distribution Channel and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版日期: | 出版商: Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

Transthyretin型心類澱粉蛋白沉積症的發生率的上升,預計促進Transthyretin型心類澱粉蛋白沉積症(ATTR-CM)治療市場成長。可是,Transthyretin型心類澱粉蛋白沉積症(ATTR-CM)相關的認識缺乏,預計妨礙市場成長。

本報告提供全球Transthyretin型心類澱粉蛋白沉積症治療市場相關調查,市場概要,市場趨勢,影響市場的因素分析,需求分析,各市場區隔、各地區的市場分析,價格分析,並提供主要企業簡介等資訊。

目錄

第1章 調查目的、前提條件

第2章 市場展望

  • 報告的說明
    • 市場定義和範圍
  • 摘要整理
    • 市場明細:各類型
    • 市場明細:各藥物類型
    • 市場明細:各流通管道
    • 市場明細:各地區
  • Coherent Opportunity Map(COM)

第3章 市場動態,法規,及趨勢分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 開發平台分析
  • 醫療費償付方案
  • 流行病學
  • PEST分析
  • 法規方案
  • 新產品的銷售
  • 合作與契約
  • 市場趨勢

第4章 全球Transthyretin型心類澱粉蛋白沉積症治療市場:冠狀病毒(Covid-19)大流行的影響

  • COVID-19:市場情境
  • COVID-19對Transthyretin型心類澱粉蛋白沉積症治療藥市場的影響

第5章 全球Transthyretin型心類澱粉蛋白沉積症治療市場:各類型

  • 簡介
  • 遺傳性Transthyretin型類澱粉蛋白沉積症(hATTR)
  • 野生型Transthyretin型類澱粉蛋白沉積症(wtATTR)

第6章 全球Transthyretin型心類澱粉蛋白沉積症治療市場:各藥物類型

  • 簡介
  • Transthyretin穩定劑
  • 非類固醇消炎劑(NSAID)
  • RNAi療法
  • 其他

第7章 全球Transthyretin型心類澱粉蛋白沉積症治療市場:各流通管道

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第8章 全球Transthyretin型心類澱粉蛋白沉積症治療市場:各地區

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東、非洲

第9章 競爭情形

  • 熱圖分析
  • 市場佔有率分析
    • Pfizer Inc.
    • GlaxoSmithKline Plc.
    • Eidos Therapeutics
    • Ionis Pharmaceuticals, Inc.
    • Alnylam Pharmaceuticals
    • Prothena Corporation plc
    • Intellia Therapeutics, Inc.
    • Corino Therapeutics, Inc.
    • Analyst Views

第10章 Section

目錄

Title:
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, by Type (Hereditary Transthyretin Amyloidosis (hATTR), and Wild Type Transthyretin Amyloidosis (wtATTR)), by Drug Type (Transthyretin Stabilizers, Nonsteroidal Anti-Inflammatory Drugs (NSAID), RNAi therapy, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a common type of amyloidosis, which affects the heart, causing heart muscles to stiffen and eventually lead to heart failure. ATTR-CM often causes symptoms of heart failure, such as fatigue, shortness of breath and peripheral edema, and other symptoms related to buildup of amyloid fibrils in the body. There are two forms of transthyretin amyloid cardiomyopathy (ATTR-CM); hereditary transthyretin amyloidosis (hATTR) and wild type transthyretin amyloidosis (wtATTR). This disease is often diagnosed only after symptoms have become severe.

Market Dynamics

Rising incidence of transthyretin amyloid cardiomyopathy is expected to drive the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market growth. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in December 2019, reports the study of the Japan Medical Data Vision (MDV), which was a hospital based database from January 2010 to September 2018 to estimate the number of currently diagnosed ATTR-CM patients. This study reports data of over 9 years of study which included 3255 patients (155.8 per million adult patients in the MDV database) to 3992 patients (191.1 per million) diagnoses of wild type transthyretin amyloidosis (wtATTR).

However, lack of awareness about transthyretin amyloid cardiomyopathy (ATTR-CM) is expected to hinder the market growth. For instance, according to an article published by Amyloidosis. Amyloidosis Foundation in 2016, awareness of transthyretin amyloid cardiomyopathy (ATTR-CM) is low among the general public as well as healthcare professionals and therefore, this condition often is unnoticed.

Key features of the study:

  • This report provides in-depth analysis of the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., Corino Therapeutics, Inc. among others
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.

Detailed Segmentation:

  • Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Type:
    • Hereditary Transthyretin Amyloidosis (hATTR)
    • Wild Type Transthyretin Amyloidosis (wtATTR)
  • Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Drug Type:
    • Transthyretin Stabilizers
    • Nonsteroidal anti-inflammatory drugs (NSAID)
    • RNAi therapy
    • Others
  • Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Region:
    • North America
      • By Type:
      • Hereditary Transthyretin Amyloidosis (hATTR)
      • Wild Type Transthyretin Amyloidosis (wtATTR)
      • By Drug Type:
      • Transthyretin Stabilizers
      • Nonsteroidal anti-inflammatory drugs (NSAID)
      • RNAi therapy
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Type:
      • Hereditary Transthyretin Amyloidosis (hATTR)
      • Wild Type Transthyretin Amyloidosis (wtATTR)
      • By Drug Type:
      • Transthyretin Stabilizers
      • Nonsteroidal anti-inflammatory drugs (NSAID)
      • RNAi therapy
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Type:
      • Hereditary Transthyretin Amyloidosis (hATTR)
      • Wild Type Transthyretin Amyloidosis (wtATTR)
      • By Drug Type:
      • Transthyretin Stabilizers
      • Nonsteroidal Anti-Inflammatory Drugs (NSAID)
      • RNAi therapy
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Type:
      • Hereditary Transthyretin Amyloidosis (hATTR)
      • Wild Type Transthyretin Amyloidosis (wtATTR)
      • By Drug Type:
      • Transthyretin Stabilizers
      • Nonsteroidal Anti-Inflammatory Drugs (NSAID)
      • RNAi therapy
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Type:
      • Hereditary Transthyretin Amyloidosis (hATTR)
      • Wild Type Transthyretin Amyloidosis (wtATTR)
      • By Drug Type:
      • Transthyretin Stabilizers
      • Nonsteroidal Anti-Inflammatory Drugs (NSAID)
      • RNAi therapy
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • Others
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Type:
      • Hereditary Transthyretin Amyloidosis (hATTR)
      • Wild Type Transthyretin Amyloidosis (wtATTR)
      • By Drug Type:
      • Transthyretin Stabilizers
      • Nonsteroidal Anti-Inflammatory Drugs (NSAID)
      • RNAi therapy
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Pfizer Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • GlaxoSmithKline Plc.
    • Eidos Therapeutics
    • Ionis Pharmaceuticals, Inc.
    • Alnylam Pharmaceuticals
    • Prothena Corporation plc
    • Intellia Therapeutics, Inc.
    • Corino Therapeutics, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Type
    • Market Snippet, By Drug Type
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Pipeline Analysis
  • Reimbursement Scenario
  • Epidemiology
  • Pest Analysis
  • Regulatory Scenario
  • New Product Launches
  • Collaborations and Agreements
  • Market Trends

4. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Market Scenario
  • Impact of COVID-19 Market on the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Products

5. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Type, 2016-2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hereditary Transthyretin Amyloidosis (hATTR)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
  • Wild Type Transthyretin Amyloidosis (wtATTR)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)

6. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Drug Type, 2016-2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Transthyretin Stabilizers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
  • Nonsteroidal anti-inflammatory drugs (NSAID)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
  • RNAi therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)

7. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Distribution Channel, 2016-2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)

8. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Region, 2016-2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2027
  • North America
    • Market Size and Forecast, By Type, 2016-2027, (US$ Mn)
    • Market Size and Forecast, By Drug Type, 2016-2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2027, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Type, 2016-2027, (US$ Mn)
    • Market Size and Forecast, By Drug Type, 2016-2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Type, 2016-2027, (US$ Mn)
    • Market Size and Forecast, By Drug Type, 2016-2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2027, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Type, 2016-2027, (US$ Mn)
    • Market Size and Forecast, By Drug Type, 2016-2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2027, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Type, 2016-2027, (US$ Mn)
    • Market Size and Forecast, By Drug Type, 2016-2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Type, 2016-2027, (US$ Mn)
    • Market Size and Forecast, By Drug Type, 2016-2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2027, (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2016-2027, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

9. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • GlaxoSmithKline Plc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Eidos Therapeutics
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Ionis Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Alnylam Pharmaceuticals
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Prothena Corporation plc
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Intellia Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Corino Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Analyst Views

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact